ID   NRG1_HUMAN              Reviewed;         640 AA.
AC   Q02297; A5YAK4; A5YAK5; A8K1L2; B7Z4Z3; E9PHH4; O14667; P98202; Q02298;
AC   Q02299; Q07110; Q07111; Q12779; Q12780; Q12781; Q12782; Q12783; Q12784;
AC   Q15491; Q7RTV9; Q7RTW0; Q7RTW1; Q7RTW2; Q8NFN1; Q8NFN2; Q8NFN3; Q9UPE3;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   28-JUN-2023, entry version 243.
DE   RecName: Full=Pro-neuregulin-1, membrane-bound isoform;
DE            Short=Pro-NRG1;
DE   Contains:
DE     RecName: Full=Neuregulin-1;
DE     AltName: Full=Acetylcholine receptor-inducing activity;
DE              Short=ARIA;
DE     AltName: Full=Breast cancer cell differentiation factor p45;
DE     AltName: Full=Glial growth factor;
DE     AltName: Full=Heregulin;
DE              Short=HRG;
DE     AltName: Full=Neu differentiation factor;
DE     AltName: Full=Sensory and motor neuron-derived factor;
DE   Flags: Precursor;
GN   Name=NRG1; Synonyms=GGF, HGL, HRGA, NDF, SMDF;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 6; 7 AND 8), AND PARTIAL PROTEIN
RP   SEQUENCE.
RX   PubMed=1350381; DOI=10.1126/science.256.5060.1205;
RA   Holmes W.E., Sliwkowski M.X., Akita R.W., Henzel W.J., Lee J., Park J.W.,
RA   Yansura D., Abadi N., Raab H., Lewis G.D., Shepard H.M., Kuang W.-J.,
RA   Wood W.I., Goeddel D.V., Vandlen R.L.;
RT   "Identification of heregulin, a specific activator of p185erbB2.";
RL   Science 256:1205-1210(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 3; 4; 6; 7 AND 8).
RC   TISSUE=Kidney adenocarcinoma, and Pituitary;
RX   PubMed=7509448; DOI=10.1128/mcb.14.3.1909-1919.1994;
RA   Wen D., Suggs S.V., Karunagaran D., Liu N., Cupples R.L., Luo Y.,
RA   Janssen A.M., Ben-Baruch N., Trollinger D.B., Jacobsen V.L., Meng S.-Y.,
RA   Lu H.S., Hu S., Chang D., Yang W., Yanigahara D., Koski R.A., Yarden Y.;
RT   "Structural and functional aspects of the multiplicity of Neu
RT   differentiation factors.";
RL   Mol. Cell. Biol. 14:1909-1919(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 8 AND 9).
RC   TISSUE=Brain;
RX   PubMed=8096067; DOI=10.1038/362312a0;
RA   Marchionni M.A., Goodearl A.D.J., Chen M.S., Bermingham-McDonogh O.,
RA   Kirk C., Hendricks M., Danehy F., Misumi D., Sudhalter J., Kobayashi K.,
RA   Wroblewski D., Lynch C., Baldasarre M., Hiles I., Davis J.B., Hsuan J.J.,
RA   Totty N.F., Otsu M., McBurney R.N., Waterfield M.D., Stroobant P.,
RA   Gwynne D.;
RT   "Glial growth factors are alternatively spliced erbB2 ligands expressed in
RT   the nervous system.";
RL   Nature 362:312-318(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 10).
RC   TISSUE=Brain stem, and Cerebellum;
RX   PubMed=7782315; DOI=10.1074/jbc.270.24.14523;
RA   Ho W.-H., Armanini M.P., Nuijens A., Phillips H.S., Osheroff P.L.;
RT   "Sensory and motor neuron-derived factor. A novel heregulin variant highly
RT   expressed in sensory and motor neurons.";
RL   J. Biol. Chem. 270:14523-14532(1995).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 10 AND 12), AND VARIANT
RP   THR-289.
RC   TISSUE=Hippocampus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M.,
RA   Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A., Chang J.L.,
RA   Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., Allen N.R., Anderson S.,
RA   Asakawa T., Blechschmidt K., Bloom T., Borowsky M.L., Butler J., Cook A.,
RA   Corum B., DeArellano K., DeCaprio D., Dooley K.T., Dorris L. III,
RA   Engels R., Gloeckner G., Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K.,
RA   Jaffe D.B., Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C., O'Leary S.B.,
RA   O'Neill K., Parker S.C.J., Polley A., Raymond C.K., Reichwald K.,
RA   Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R., Smith C.L.,
RA   Sneddon T.P., Talamas J.A., Tenzin P., Topham K., Venkataraman V., Wen G.,
RA   Yamazaki S., Young S.K., Zeng Q., Zimmer A.R., Rosenthal A., Birren B.W.,
RA   Platzer M., Shimizu N., Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF GAMMA-HEREGULIN FUSION PROTEIN.
RC   TISSUE=Mammary cancer;
RX   PubMed=9333014; DOI=10.1038/sj.onc.1201317;
RA   Schaefer G., Fitzpatrick V.D., Sliwkowski M.X.;
RT   "Gamma-heregulin: a novel heregulin isoform that is an autocrine growth
RT   factor for the human breast cancer cell line, MDA-MB-175.";
RL   Oncogene 15:1385-1394(1997).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 1; 3; 8 AND 9), AND
RP   SUSCEPTIBILITY TO SCHIZOPHRENIA.
RX   PubMed=12145742; DOI=10.1086/342734;
RA   Stefansson H., Sigurdsson E., Steinthorsdottir V., Bjornsdottir S.,
RA   Sigmundsson T., Ghosh S., Brynjolfsson J., Gunnarsdottir S., Ivarsson O.,
RA   Chou T.T., Hjaltason O., Birgisdottir B., Jonsson H., Gudnadottir V.G.,
RA   Gudmundsdottir E., Bjornsson A., Ingvarsson B., Ingason A., Sigfusson S.,
RA   Hardardottir H., Harvey R.P., Brunner D., Mutel V., Gonzalo A., Lemke G.,
RA   Sainz J., Johannesson G., Andresson T., Gudbjartsson D., Manolescu A.,
RA   Frigge M.L., Gurney M.E., Kong A., Gulcher J.R., Petursson H.,
RA   Stefansson K.;
RT   "Neuregulin 1 and susceptibility to Schizophrenia.";
RL   Am. J. Hum. Genet. 71:877-892(2002).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 11), ALTERNATIVE SPLICING, VARIANTS
RP   GLN-38 AND THR-289, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.
RC   TISSUE=Hippocampus, and Prefrontal cortex;
RX   PubMed=17565985; DOI=10.1074/jbc.m702953200;
RA   Tan W., Wang Y., Gold B., Chen J., Dean M., Harrison P.J., Weinberger D.R.,
RA   Law A.J.;
RT   "Molecular cloning of a brain-specific, developmentally regulated
RT   neuregulin 1 (NRG1) isoform and identification of a functional promoter
RT   variant associated with schizophrenia.";
RL   J. Biol. Chem. 282:24343-24351(2007).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 10).
RC   TISSUE=Brain, and Duodenum;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-211 (ISOFORM 1).
RA   Schoumacher F., Herzer S., Flury N., Kueng W., Mueller H., Eppenberger U.;
RL   Submitted (SEP-1997) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   PROTEIN SEQUENCE OF 20-28.
RX   PubMed=7689552; DOI=10.1016/s0021-9258(17)46636-1;
RA   Culouscou J.-M., Plowman G.D., Carlton G.W., Green J.M., Shoyab M.;
RT   "Characterization of a breast cancer cell differentiation factor that
RT   specifically activates the HER4/p180erbB4 receptor.";
RL   J. Biol. Chem. 268:18407-18410(1993).
RN   [14]
RP   PARTIAL PROTEIN SEQUENCE (ISOFORM 1), FUNCTION, AND GLYCOSYLATION.
RX   PubMed=1348215; DOI=10.1016/0092-8674(92)90131-u;
RA   Peles E., Bacus S.S., Koski R.A., Lu H.S., Wen D., Ogden S.G., Levy R.B.,
RA   Yarden Y.;
RT   "Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that
RT   induces differentiation of mammary tumor cells.";
RL   Cell 69:205-216(1992).
RN   [15]
RP   BINDING TO ERBB4, AND FUNCTION.
RX   PubMed=7902537; DOI=10.1038/366473a0;
RA   Plowman G.D., Green J.M., Culouscou J.M., Carlton G.W., Rothwell V.M.,
RA   Buckley S.;
RT   "Heregulin induces tyrosine phosphorylation of HER4/p180erbB4.";
RL   Nature 366:473-475(1993).
RN   [16]
RP   CHROMOSOMAL TRANSLOCATION.
RX   PubMed=10523851; DOI=10.1038/sj.onc.1202950;
RA   Wang X.-Z., Jolicoeur E.M., Conte N., Chaffanet M., Zhang Y.,
RA   Mozziconacci M.-J., Feiner H., Birnbaum D., Pebusque M.-J., Ron D.;
RT   "Gamma-heregulin is the product of a chromosomal translocation fusing the
RT   DOC4 and HGL/NRG1 genes in the MDA-MB-175 breast cancer cell line.";
RL   Oncogene 18:5718-5721(1999).
RN   [17]
RP   CHROMOSOMAL TRANSLOCATION.
RX   PubMed=10597312; DOI=10.1038/sj.onc.1203136;
RA   Liu X., Baker E., Eyre H.J., Sutherland G.R., Zhou M.;
RT   "Gamma-heregulin: a fusion gene of DOC-4 and neuregulin-1 derived from a
RT   chromosome translocation.";
RL   Oncogene 18:7110-7114(1999).
RN   [18]
RP   BINDING TO ERBB4.
RX   PubMed=10867024; DOI=10.1074/jbc.c901015199;
RA   Sweeney C., Lai C., Riese D.J. II, Diamonti A.J., Cantley L.C.,
RA   Carraway K.L. III;
RT   "Ligand discrimination in signaling through an ErbB4 receptor homodimer.";
RL   J. Biol. Chem. 275:19803-19807(2000).
RN   [19]
RP   FUNCTION, BINDING TO ERBB3 AND INTEGRINS, IDENTIFICATION IN A TERNARY
RP   COMPLEX WITH ERBB3 AND INTEGRINS, AND MUTAGENESIS OF LYS-181; LYS-185 AND
RP   LYS-187.
RX   PubMed=20682778; DOI=10.1074/jbc.m110.113878;
RA   Ieguchi K., Fujita M., Ma Z., Davari P., Taniguchi Y., Sekiguchi K.,
RA   Wang B., Takada Y.K., Takada Y.;
RT   "Direct binding of the EGF-like domain of neuregulin-1 to integrins
RT   ({alpha}v{beta}3 and {alpha}6{beta}4) is involved in neuregulin-1/ErbB
RT   signaling.";
RL   J. Biol. Chem. 285:31388-31398(2010).
RN   [20]
RP   STRUCTURE BY NMR OF 175-241 (ISOFORM 1).
RX   PubMed=8062828; DOI=10.1002/j.1460-2075.1994.tb06658.x;
RA   Nagata K., Kohda D., Hatanaka H., Ichikawa S., Matsuda S., Yamamoto T.,
RA   Suzuki A., Inagaki F.;
RT   "Solution structure of the epidermal growth factor-like domain of
RT   heregulin-alpha, a ligand for p180erbB-4.";
RL   EMBO J. 13:3517-3523(1994).
RN   [21]
RP   STRUCTURE BY NMR OF 177-239 (ISOFORM 1), AND DISULFIDE BONDS.
RX   PubMed=8639490; DOI=10.1021/bi952626l;
RA   Jacobsen N.E., Abadi N., Sliwkowski M.X., Reilly D., Skelton N.J.,
RA   Fairbrother W.J.;
RT   "High-resolution solution structure of the EGF-like domain of heregulin-
RT   alpha.";
RL   Biochemistry 35:3402-3417(1996).
CC   -!- FUNCTION: Direct ligand for ERBB3 and ERBB4 tyrosine kinase receptors.
CC       Concomitantly recruits ERBB1 and ERBB2 coreceptors, resulting in
CC       ligand-stimulated tyrosine phosphorylation and activation of the ERBB
CC       receptors. The multiple isoforms perform diverse functions such as
CC       inducing growth and differentiation of epithelial, glial, neuronal, and
CC       skeletal muscle cells; inducing expression of acetylcholine receptor in
CC       synaptic vesicles during the formation of the neuromuscular junction;
CC       stimulating lobuloalveolar budding and milk production in the mammary
CC       gland and inducing differentiation of mammary tumor cells; stimulating
CC       Schwann cell proliferation; implication in the development of the
CC       myocardium such as trabeculation of the developing heart. Isoform 10
CC       may play a role in motor and sensory neuron development. Binds to ERBB4
CC       (PubMed:10867024, PubMed:7902537). Binds to ERBB3 (PubMed:20682778).
CC       Acts as a ligand for integrins and binds (via EGF domain) to integrins
CC       ITGAV:ITGB3 or ITGA6:ITGB4. Its binding to integrins and subsequent
CC       ternary complex formation with integrins and ERRB3 are essential for
CC       NRG1-ERBB signaling. Induces the phosphorylation and activation of
CC       MAPK3/ERK1, MAPK1/ERK2 and AKT1 (PubMed:20682778). Ligand-dependent
CC       ERBB4 endocytosis is essential for the NRG1-mediated activation of
CC       these kinases in neurons (By similarity).
CC       {ECO:0000250|UniProtKB:P43322, ECO:0000269|PubMed:10867024,
CC       ECO:0000269|PubMed:1348215, ECO:0000269|PubMed:20682778,
CC       ECO:0000269|PubMed:7902537}.
CC   -!- SUBUNIT: The cytoplasmic domain interacts with the LIM domain region of
CC       LIMK1 (By similarity). Forms a ternary complex with ERBB3 and
CC       ITGAV:ITGB3 or ITGA6:ITGB4 (PubMed:20682778). Interacts with NRDC and
CC       BACE1 (By similarity). {ECO:0000250|UniProtKB:P43322,
CC       ECO:0000250|UniProtKB:Q6DR98, ECO:0000269|PubMed:20682778}.
CC   -!- INTERACTION:
CC       Q02297-6; P21860: ERBB3; NbExp=2; IntAct=EBI-15651799, EBI-720706;
CC       Q02297-6; Q15303: ERBB4; NbExp=3; IntAct=EBI-15651799, EBI-80371;
CC       Q02297-7; P04626: ERBB2; NbExp=2; IntAct=EBI-2460927, EBI-641062;
CC       Q02297-7; P21860: ERBB3; NbExp=3; IntAct=EBI-2460927, EBI-720706;
CC       Q02297-10; P07307-3: ASGR2; NbExp=3; IntAct=EBI-12842334, EBI-12808270;
CC       Q02297-10; P21854: CD72; NbExp=3; IntAct=EBI-12842334, EBI-307924;
CC       Q02297-10; Q8N5M9: JAGN1; NbExp=3; IntAct=EBI-12842334, EBI-10266796;
CC       Q02297-10; Q86VI4: LAPTM4B; NbExp=3; IntAct=EBI-12842334, EBI-3267258;
CC       Q02297-10; Q96JQ5: MS4A4A; NbExp=3; IntAct=EBI-12842334, EBI-12820341;
CC       Q02297-10; P60201-2: PLP1; NbExp=3; IntAct=EBI-12842334, EBI-12188331;
CC       Q02297-10; Q969K7: TMEM54; NbExp=3; IntAct=EBI-12842334, EBI-3922833;
CC   -!- SUBCELLULAR LOCATION: [Pro-neuregulin-1, membrane-bound isoform]: Cell
CC       membrane; Single-pass type I membrane protein. Note=Does not seem to be
CC       active.
CC   -!- SUBCELLULAR LOCATION: [Neuregulin-1]: Secreted.
CC   -!- SUBCELLULAR LOCATION: [Isoform 8]: Nucleus. Note=May be nuclear.
CC   -!- SUBCELLULAR LOCATION: [Isoform 9]: Secreted. Note=Has a signal peptide.
CC   -!- SUBCELLULAR LOCATION: [Isoform 10]: Membrane; Single-pass type I
CC       membrane protein. Note=May possess an internal uncleaved signal
CC       sequence.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=11;
CC         Comment=Additional isoforms seem to exist. Isoforms have been
CC         classified as type I NRGs (isoforms with an Ig domain and a
CC         glycosylation domain, isoforms 1-8), type II NRGs (isoforms with an
CC         Ig domain but no glycosylation domain, isoform 9), type III NRGs
CC         (isoforms with a Cys-rich domain, isoform 10) and type IV NRGs
CC         (isoforms with additional 5' exons, isoform 11). All these isoforms
CC         perform distinct tissue-specific functions.;
CC       Name=1; Synonyms=Alpha;
CC         IsoId=Q02297-1; Sequence=Displayed;
CC       Name=2; Synonyms=Alpha1A;
CC         IsoId=Q02297-2; Sequence=VSP_003431;
CC       Name=3; Synonyms=Alpha2B;
CC         IsoId=Q02297-3; Sequence=VSP_003434, VSP_003435;
CC       Name=4; Synonyms=Alpha3;
CC         IsoId=Q02297-4; Sequence=VSP_003432, VSP_003433;
CC       Name=6; Synonyms=Beta1, Beta1A;
CC         IsoId=Q02297-6; Sequence=VSP_003428;
CC       Name=7; Synonyms=Beta2;
CC         IsoId=Q02297-7; Sequence=VSP_003427;
CC       Name=8; Synonyms=Beta3, GGFHFB1;
CC         IsoId=Q02297-8; Sequence=VSP_003429, VSP_003430;
CC       Name=9; Synonyms=GGF2, GGFHPP2;
CC         IsoId=Q02297-9; Sequence=VSP_003425, VSP_003426, VSP_003429,
CC                                  VSP_003430;
CC       Name=10; Synonyms=SMDF;
CC         IsoId=Q02297-10; Sequence=VSP_037562, VSP_037565, VSP_003429,
CC                                   VSP_003430;
CC       Name=11; Synonyms=Type IV-beta1a;
CC         IsoId=Q02297-11; Sequence=VSP_037563, VSP_037564, VSP_003426,
CC                                   VSP_003428;
CC       Name=12;
CC         IsoId=Q02297-12; Sequence=VSP_003427, VSP_046417;
CC   -!- TISSUE SPECIFICITY: Type I isoforms are the predominant forms expressed
CC       in the endocardium. Isoform alpha is expressed in breast, ovary,
CC       testis, prostate, heart, skeletal muscle, lung, placenta liver, kidney,
CC       salivary gland, small intestine and brain, but not in uterus, stomach,
CC       pancreas, and spleen. Isoform 3 is the predominant form in mesenchymal
CC       cells and in non-neuronal organs, whereas isoform 6 is the major
CC       neuronal form. Isoform 8 is expressed in spinal cord and brain. Isoform
CC       9 is the major form in skeletal muscle cells; in the nervous system it
CC       is expressed in spinal cord and brain. Also detected in adult heart,
CC       placenta, lung, liver, kidney, and pancreas. Isoform 10 is expressed in
CC       nervous system: spinal cord motor neurons, dorsal root ganglion
CC       neurons, and brain. Predominant isoform expressed in sensory and motor
CC       neurons. Not detected in adult heart, placenta, lung, liver, skeletal
CC       muscle, kidney, and pancreas. Not expressed in fetal lung, liver and
CC       kidney. Type IV isoforms are brain-specific.
CC       {ECO:0000269|PubMed:17565985}.
CC   -!- DEVELOPMENTAL STAGE: Detectable at early embryonic ages. Isoform 10 is
CC       highly expressed in developing spinal motor neurons and in developing
CC       cranial nerve nuclei. Expression is maintained only in both adult motor
CC       neurons and dorsal root ganglion neurons. Type IV isoforms are
CC       expressed in fetal brain. {ECO:0000269|PubMed:17565985}.
CC   -!- DOMAIN: The cytoplasmic domain may be involved in the regulation of
CC       trafficking and proteolytic processing. Regulation of the proteolytic
CC       processing involves initial intracellular domain dimerization (By
CC       similarity). {ECO:0000250}.
CC   -!- DOMAIN: ERBB receptor binding is elicited entirely by the EGF-like
CC       domain.
CC   -!- PTM: Proteolytic cleavage close to the plasma membrane on the external
CC       face leads to the release of the soluble growth factor form.
CC   -!- PTM: N- and O-glycosylated. Extensive glycosylation precedes the
CC       proteolytic cleavage (By similarity). {ECO:0000250}.
CC   -!- DISEASE: Note=A chromosomal aberration involving NRG1 produces gamma-
CC       heregulin. Translocation t(8;11) with TENM4. The translocation fuses
CC       the 5'-end of TENM4 to NRG1 (isoform 8). The product of this
CC       translocation was first thought to be an alternatively spliced isoform.
CC       Gamma-heregulin is a soluble activating ligand for the ERBB2-ERBB3
CC       receptor complex and acts as an autocrine growth factor in a specific
CC       breast cancer cell line (MDA-MB-175). Not detected in breast carcinoma
CC       samples, including ductal, lobular, medullary, and mucinous
CC       histological types, neither in other breast cancer cell lines.
CC   -!- MISCELLANEOUS: [Isoform 10]: Potential internal signal sequence at
CC       positions 76-100. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the neuregulin family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA19955.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the N-terminal part.; Evidence={ECO:0000305};
CC       Sequence=AAC51756.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Protein Spotlight; Note=Tipping the mind - Issue 129
CC       of June 2011;
CC       URL="https://web.expasy.org/spotlight/back_issues/129";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M94165; AAA58638.1; -; mRNA.
DR   EMBL; M94166; AAA58639.1; -; mRNA.
DR   EMBL; M94167; AAA58640.1; -; mRNA.
DR   EMBL; M94168; AAA58641.1; -; mRNA.
DR   EMBL; U02325; AAA19950.1; -; mRNA.
DR   EMBL; U02326; AAA19951.1; -; mRNA.
DR   EMBL; U02327; AAA19952.1; -; mRNA.
DR   EMBL; U02328; AAA19953.1; -; mRNA.
DR   EMBL; U02329; AAA19954.1; -; mRNA.
DR   EMBL; U02330; AAA19955.1; ALT_SEQ; mRNA.
DR   EMBL; L12260; AAB59622.1; -; mRNA.
DR   EMBL; L12261; AAB59358.1; -; mRNA.
DR   EMBL; L41827; AAC41764.1; -; mRNA.
DR   EMBL; AK289927; BAF82616.1; -; mRNA.
DR   EMBL; AK298132; BAH12729.1; -; mRNA.
DR   EMBL; AC021909; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC022833; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC022850; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC023948; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC068359; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC068931; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC083977; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC103675; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC104000; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC104029; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC113209; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AF009227; AAC51756.1; ALT_INIT; mRNA.
DR   EMBL; AF491780; AAM71137.1; -; Genomic_DNA.
DR   EMBL; AF491780; AAM71139.1; -; Genomic_DNA.
DR   EMBL; AF491780; AAM71140.1; -; Genomic_DNA.
DR   EMBL; EF372273; ABQ53539.1; -; mRNA.
DR   EMBL; EF372274; ABQ53540.1; -; mRNA.
DR   EMBL; CH471080; EAW63411.1; -; Genomic_DNA.
DR   EMBL; BC064587; AAH64587.1; -; mRNA.
DR   EMBL; BC073871; AAH73871.1; -; mRNA.
DR   EMBL; AF026146; AAD01795.1; -; mRNA.
DR   EMBL; BK000383; DAA00044.1; -; Genomic_DNA.
DR   EMBL; BK000383; DAA00045.1; -; Genomic_DNA.
DR   EMBL; BK000383; DAA00046.1; -; Genomic_DNA.
DR   EMBL; BK000383; DAA00047.1; -; Genomic_DNA.
DR   CCDS; CCDS47836.1; -. [Q02297-9]
DR   CCDS; CCDS55218.1; -. [Q02297-11]
DR   CCDS; CCDS55219.1; -. [Q02297-12]
DR   CCDS; CCDS6083.1; -. [Q02297-6]
DR   CCDS; CCDS6084.1; -. [Q02297-7]
DR   CCDS; CCDS6085.1; -. [Q02297-1]
DR   CCDS; CCDS6086.1; -. [Q02297-3]
DR   CCDS; CCDS6087.1; -. [Q02297-10]
DR   CCDS; CCDS94274.1; -. [Q02297-8]
DR   PIR; A43273; A43273.
DR   PIR; A56943; A56943.
DR   PIR; B43273; B43273.
DR   PIR; C43273; C43273.
DR   PIR; D43273; D43273.
DR   PIR; I38403; I38403.
DR   PIR; I38404; I38404.
DR   PIR; I38408; I38408.
DR   PIR; S32357; S32357.
DR   RefSeq; NP_001153467.1; NM_001159995.2.
DR   RefSeq; NP_001153471.1; NM_001159999.2.
DR   RefSeq; NP_001153473.1; NM_001160001.2. [Q02297-11]
DR   RefSeq; NP_001153477.1; NM_001160005.1.
DR   RefSeq; NP_001153480.1; NM_001160008.1. [Q02297-12]
DR   RefSeq; NP_001309134.1; NM_001322205.1.
DR   RefSeq; NP_001309135.1; NM_001322206.1.
DR   RefSeq; NP_001309136.1; NM_001322207.1.
DR   RefSeq; NP_039250.2; NM_013956.4. [Q02297-6]
DR   RefSeq; NP_039251.2; NM_013957.4. [Q02297-7]
DR   RefSeq; NP_039252.2; NM_013958.3. [Q02297-8]
DR   RefSeq; NP_039253.1; NM_013959.3. [Q02297-10]
DR   RefSeq; NP_039254.1; NM_013960.4. [Q02297-3]
DR   RefSeq; NP_039256.2; NM_013962.2. [Q02297-9]
DR   RefSeq; NP_039258.1; NM_013964.4. [Q02297-1]
DR   PDB; 1HAE; NMR; -; A=177-239.
DR   PDB; 1HAF; NMR; -; A=177-239.
DR   PDB; 1HRE; NMR; -; A=175-241.
DR   PDB; 1HRF; NMR; -; A=175-241.
DR   PDB; 3U7U; X-ray; 3.03 A; G/H/I/J/K/L=175-212.
DR   PDB; 7MN5; EM; 2.93 A; H=176-237.
DR   PDB; 7MN6; EM; 3.09 A; H=176-237.
DR   PDB; 7MN8; EM; 3.45 A; H=176-237.
DR   PDB; 7SJL; NMR; -; A=34-133.
DR   PDBsum; 1HAE; -.
DR   PDBsum; 1HAF; -.
DR   PDBsum; 1HRE; -.
DR   PDBsum; 1HRF; -.
DR   PDBsum; 3U7U; -.
DR   PDBsum; 7MN5; -.
DR   PDBsum; 7MN6; -.
DR   PDBsum; 7MN8; -.
DR   PDBsum; 7SJL; -.
DR   AlphaFoldDB; Q02297; -.
DR   SMR; Q02297; -.
DR   BioGRID; 109332; 107.
DR   CORUM; Q02297; -.
DR   DIP; DIP-355N; -.
DR   IntAct; Q02297; 56.
DR   MINT; Q02297; -.
DR   STRING; 9606.ENSP00000384620; -.
DR   GlyCosmos; Q02297; 3 sites, No reported glycans.
DR   GlyGen; Q02297; 4 sites, 1 O-linked glycan (1 site).
DR   iPTMnet; Q02297; -.
DR   PhosphoSitePlus; Q02297; -.
DR   BioMuta; NRG1; -.
DR   DMDM; 9297018; -.
DR   jPOST; Q02297; -.
DR   MassIVE; Q02297; -.
DR   MaxQB; Q02297; -.
DR   PaxDb; Q02297; -.
DR   PeptideAtlas; Q02297; -.
DR   ProteomicsDB; 20533; -.
DR   ProteomicsDB; 58070; -. [Q02297-1]
DR   ProteomicsDB; 58071; -. [Q02297-10]
DR   ProteomicsDB; 58072; -. [Q02297-11]
DR   ProteomicsDB; 58073; -. [Q02297-2]
DR   ProteomicsDB; 58074; -. [Q02297-3]
DR   ProteomicsDB; 58075; -. [Q02297-4]
DR   ProteomicsDB; 58076; -. [Q02297-6]
DR   ProteomicsDB; 58077; -. [Q02297-7]
DR   ProteomicsDB; 58078; -. [Q02297-8]
DR   ProteomicsDB; 58079; -. [Q02297-9]
DR   ABCD; Q02297; 1 sequenced antibody.
DR   Antibodypedia; 3706; 1075 antibodies from 45 providers.
DR   DNASU; 3084; -.
DR   Ensembl; ENST00000287842.7; ENSP00000287842.4; ENSG00000157168.21. [Q02297-6]
DR   Ensembl; ENST00000356819.7; ENSP00000349275.6; ENSG00000157168.21. [Q02297-7]
DR   Ensembl; ENST00000405005.8; ENSP00000384620.2; ENSG00000157168.21. [Q02297-1]
DR   Ensembl; ENST00000519301.6; ENSP00000429582.1; ENSG00000157168.21. [Q02297-11]
DR   Ensembl; ENST00000520407.5; ENSP00000434640.1; ENSG00000157168.21. [Q02297-9]
DR   Ensembl; ENST00000520502.7; ENSP00000433289.1; ENSG00000157168.21. [Q02297-10]
DR   Ensembl; ENST00000521670.5; ENSP00000428828.1; ENSG00000157168.21. [Q02297-3]
DR   Ensembl; ENST00000523079.5; ENSP00000430120.1; ENSG00000157168.21. [Q02297-12]
DR   Ensembl; ENST00000650919.1; ENSP00000498811.1; ENSG00000157168.21. [Q02297-8]
DR   GeneID; 3084; -.
DR   KEGG; hsa:3084; -.
DR   MANE-Select; ENST00000405005.8; ENSP00000384620.2; NM_013964.5; NP_039258.1.
DR   UCSC; uc003xip.4; human. [Q02297-1]
DR   AGR; HGNC:7997; -.
DR   CTD; 3084; -.
DR   DisGeNET; 3084; -.
DR   GeneCards; NRG1; -.
DR   HGNC; HGNC:7997; NRG1.
DR   HPA; ENSG00000157168; Tissue enhanced (brain).
DR   MalaCards; NRG1; -.
DR   MIM; 142445; gene.
DR   neXtProt; NX_Q02297; -.
DR   OpenTargets; ENSG00000157168; -.
DR   PharmGKB; PA31776; -.
DR   VEuPathDB; HostDB:ENSG00000157168; -.
DR   eggNOG; ENOG502QRUM; Eukaryota.
DR   GeneTree; ENSGT00940000157326; -.
DR   HOGENOM; CLU_023628_1_0_1; -.
DR   InParanoid; Q02297; -.
DR   OMA; HSWSTGQ; -.
DR   OrthoDB; 3025258at2759; -.
DR   PhylomeDB; Q02297; -.
DR   TreeFam; TF332469; -.
DR   PathwayCommons; Q02297; -.
DR   Reactome; R-HSA-1227986; Signaling by ERBB2. [Q02297-10]
DR   Reactome; R-HSA-1236394; Signaling by ERBB4. [Q02297-10]
DR   Reactome; R-HSA-1250196; SHC1 events in ERBB2 signaling. [Q02297-10]
DR   Reactome; R-HSA-1250342; PI3K events in ERBB4 signaling.
DR   Reactome; R-HSA-1250347; SHC1 events in ERBB4 signaling.
DR   Reactome; R-HSA-1251985; Nuclear signaling by ERBB4.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling. [Q02297-10]
DR   Reactome; R-HSA-1306955; GRB7 events in ERBB2 signaling. [Q02297-10]
DR   Reactome; R-HSA-1358803; Downregulation of ERBB2:ERBB3 signaling. [Q02297-10]
DR   Reactome; R-HSA-1963640; GRB2 events in ERBB2 signaling.
DR   Reactome; R-HSA-1963642; PI3K events in ERBB2 signaling. [Q02297-10]
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer. [Q02297-10]
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade. [Q02297-10]
DR   Reactome; R-HSA-6785631; ERBB2 Regulates Cell Motility. [Q02297-10]
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. [Q02297-10]
DR   Reactome; R-HSA-8847993; ERBB2 Activates PTK6 Signaling. [Q02297-10]
DR   Reactome; R-HSA-8863795; Downregulation of ERBB2 signaling. [Q02297-10]
DR   Reactome; R-HSA-9620244; Long-term potentiation.
DR   Reactome; R-HSA-9664565; Signaling by ERBB2 KD Mutants. [Q02297-10]
DR   Reactome; R-HSA-9665686; Signaling by ERBB2 TMD/JMD mutants. [Q02297-10]
DR   SignaLink; Q02297; -.
DR   SIGNOR; Q02297; -.
DR   BioGRID-ORCS; 3084; 12 hits in 1160 CRISPR screens.
DR   ChiTaRS; NRG1; human.
DR   EvolutionaryTrace; Q02297; -.
DR   GeneWiki; Neuregulin_1; -.
DR   GenomeRNAi; 3084; -.
DR   Pharos; Q02297; Tbio.
DR   PRO; PR:Q02297; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   RNAct; Q02297; protein.
DR   Bgee; ENSG00000157168; Expressed in ventricular zone and 140 other tissues.
DR   ExpressionAtlas; Q02297; baseline and differential.
DR   Genevisible; Q02297; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0098978; C:glutamatergic synapse; IDA:SynGO.
DR   GO; GO:0016020; C:membrane; NAS:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0045499; F:chemorepellent activity; IBA:GO_Central.
DR   GO; GO:0005125; F:cytokine activity; TAS:BHF-UCL.
DR   GO; GO:0043125; F:ErbB-3 class receptor binding; IDA:BHF-UCL.
DR   GO; GO:0008083; F:growth factor activity; IDA:BHF-UCL.
DR   GO; GO:0005178; F:integrin binding; IDA:UniProtKB.
DR   GO; GO:0030296; F:protein tyrosine kinase activator activity; IDA:BHF-UCL.
DR   GO; GO:0048018; F:receptor ligand activity; IDA:MGI.
DR   GO; GO:0030971; F:receptor tyrosine kinase binding; NAS:UniProtKB.
DR   GO; GO:0005102; F:signaling receptor binding; IPI:BHF-UCL.
DR   GO; GO:0003712; F:transcription coregulator activity; IDA:MGI.
DR   GO; GO:0030297; F:transmembrane receptor protein tyrosine kinase activator activity; NAS:UniProtKB.
DR   GO; GO:0032148; P:activation of protein kinase B activity; IMP:UniProtKB.
DR   GO; GO:0007171; P:activation of transmembrane receptor protein tyrosine kinase activity; IDA:BHF-UCL.
DR   GO; GO:0048513; P:animal organ development; IBA:GO_Central.
DR   GO; GO:0055007; P:cardiac muscle cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0060379; P:cardiac muscle cell myoblast differentiation; IDA:BHF-UCL.
DR   GO; GO:0007154; P:cell communication; TAS:BHF-UCL.
DR   GO; GO:0030154; P:cell differentiation; IBA:GO_Central.
DR   GO; GO:0008283; P:cell population proliferation; IDA:BHF-UCL.
DR   GO; GO:0060956; P:endocardial cell differentiation; IDA:BHF-UCL.
DR   GO; GO:0038127; P:ERBB signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0038133; P:ERBB2-ERBB3 signaling pathway; IDA:MGI.
DR   GO; GO:0038135; P:ERBB2-ERBB4 signaling pathway; IDA:MGI.
DR   GO; GO:0038129; P:ERBB3 signaling pathway; IDA:CAFA.
DR   GO; GO:0038130; P:ERBB4 signaling pathway; IDA:UniProtKB.
DR   GO; GO:0038138; P:ERBB4-ERBB4 signaling pathway; IDA:MGI.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0030879; P:mammary gland development; TAS:BHF-UCL.
DR   GO; GO:0010667; P:negative regulation of cardiac muscle cell apoptotic process; IDA:BHF-UCL.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; IDA:MGI.
DR   GO; GO:2001240; P:negative regulation of extrinsic apoptotic signaling pathway in absence of ligand; IDA:BHF-UCL.
DR   GO; GO:0051048; P:negative regulation of secretion; IDA:BHF-UCL.
DR   GO; GO:0007399; P:nervous system development; IBA:GO_Central.
DR   GO; GO:0014032; P:neural crest cell development; TAS:BHF-UCL.
DR   GO; GO:0060045; P:positive regulation of cardiac muscle cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0045785; P:positive regulation of cell adhesion; IDA:BHF-UCL.
DR   GO; GO:0030307; P:positive regulation of cell growth; IDA:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:1900086; P:positive regulation of peptidyl-tyrosine autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0031334; P:positive regulation of protein-containing complex assembly; IDA:BHF-UCL.
DR   GO; GO:0051155; P:positive regulation of striated muscle cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0099149; P:regulation of postsynaptic neurotransmitter receptor internalization; IDA:SynGO.
DR   GO; GO:0051238; P:sequestering of metal ion; EXP:DisProt.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0055012; P:ventricular cardiac muscle cell differentiation; IDA:BHF-UCL.
DR   GO; GO:0003222; P:ventricular trabecula myocardium morphogenesis; IDA:BHF-UCL.
DR   GO; GO:0042060; P:wound healing; IDA:BHF-UCL.
DR   CDD; cd00054; EGF_CA; 1.
DR   CDD; cd05895; Ig_Pro_neuregulin-1; 1.
DR   DisProt; DP01520; -. [Q02297-10]
DR   Gene3D; 2.60.40.10; Immunoglobulins; 1.
DR   Gene3D; 2.10.25.10; Laminin; 1.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR040180; Neuregulin.
DR   InterPro; IPR002154; Neuregulin_C.
DR   InterPro; IPR018250; NRG1.
DR   PANTHER; PTHR11100; HEREGULIN-NEUREGULIN FAMILY MEMBER; 1.
DR   PANTHER; PTHR11100:SF7; PRO-NEUREGULIN-1, MEMBRANE-BOUND ISOFORM; 1.
DR   Pfam; PF00008; EGF; 1.
DR   Pfam; PF07679; I-set; 1.
DR   Pfam; PF02158; Neuregulin; 1.
DR   PRINTS; PR01089; NEUREGULIN.
DR   SMART; SM00181; EGF; 1.
DR   SMART; SM00409; IG; 1.
DR   SMART; SM00408; IGc2; 1.
DR   SUPFAM; SSF57196; EGF/Laminin; 1.
DR   SUPFAM; SSF48726; Immunoglobulin; 1.
DR   PROSITE; PS00022; EGF_1; 1.
DR   PROSITE; PS01186; EGF_2; 1.
DR   PROSITE; PS50026; EGF_3; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane;
KW   Chromosomal rearrangement; Direct protein sequencing; Disulfide bond;
KW   EGF-like domain; Glycoprotein; Growth factor; Immunoglobulin domain;
KW   Membrane; Nucleus; Reference proteome; Secreted; Transmembrane;
KW   Transmembrane helix.
FT   PROPEP          1..19
FT                   /evidence="ECO:0000269|PubMed:7689552"
FT                   /id="PRO_0000019462"
FT   CHAIN           20..640
FT                   /note="Pro-neuregulin-1, membrane-bound isoform"
FT                   /id="PRO_0000019463"
FT   CHAIN           20..241
FT                   /note="Neuregulin-1"
FT                   /id="PRO_0000019464"
FT   TOPO_DOM        20..242
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        243..265
FT                   /note="Helical; Note=Internal signal sequence"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        266..640
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          37..128
FT                   /note="Ig-like C2-type"
FT   DOMAIN          178..222
FT                   /note="EGF-like"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   REGION          1..53
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          334..360
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          375..399
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          433..461
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          524..588
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        375..389
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        559..573
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            34
FT                   /note="Breakpoint for translocation to form gamma-
FT                   heregulin"
FT   CARBOHYD        120
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        126
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        164
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        57..112
FT                   /evidence="ECO:0000250"
FT   DISULFID        182..196
FT                   /evidence="ECO:0000269|PubMed:8639490"
FT   DISULFID        190..210
FT                   /evidence="ECO:0000269|PubMed:8639490"
FT   DISULFID        212..221
FT                   /evidence="ECO:0000269|PubMed:8639490"
FT   VAR_SEQ         1..166
FT                   /note="Missing (in isoform 10)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:7782315"
FT                   /id="VSP_037562"
FT   VAR_SEQ         1..33
FT                   /note="MSERKEGRGKGKGKKKERGSGKKPESAAGSQSP -> MRWRRAPRRSGRPGP
FT                   RAQRPGSAARSSPPLPLLPLLLLLGTAALAPGAAAGNEAAPAGASVCYSSPPSVGSVQE
FT                   LAQRAAVVIEGKVHPQRRQQGALDRKAAAAAGEAGAWGGDREPPAAGPRALGPPAEEPL
FT                   LAANGTVPSWPTAPVPSAGEPGEEAPYLVKVHQVWAVKAGGLKKDSLLTVRLGTWGHPA
FT                   FPSCGRLKEDSRYIFFMEPDANSTSRAPAAFRASFPPLETGRNLKKEVSRVLCKRC
FT                   (in isoform 9)"
FT                   /evidence="ECO:0000303|PubMed:8096067"
FT                   /id="VSP_003425"
FT   VAR_SEQ         1..21
FT                   /note="Missing (in isoform 11)"
FT                   /evidence="ECO:0000303|PubMed:17565985"
FT                   /id="VSP_037563"
FT   VAR_SEQ         22..33
FT                   /note="KKPESAAGSQSP -> MGKGRAGRVGTT (in isoform 11)"
FT                   /evidence="ECO:0000303|PubMed:17565985"
FT                   /id="VSP_037564"
FT   VAR_SEQ         134..168
FT                   /note="EIITGMPASTEGAYVSSESPIRISVSTEGANTSSS -> A (in isoform
FT                   9 and isoform 11)"
FT                   /evidence="ECO:0000303|PubMed:17565985,
FT                   ECO:0000303|PubMed:8096067"
FT                   /id="VSP_003426"
FT   VAR_SEQ         167
FT                   /note="S -> MEIYSPDMSEVAAERSSSPSTQLSADPSLDGLPAAEDMPEPQTEDGR
FT                   TPGLVGLAVPCCACLEAERLRGCLNSEKICIVPILACLVSLCLCIAGLKWVFVDKIFEY
FT                   DSPTHLDPGGLGQDPIISLDATAASAVWVSSEAYTSPVSRAQSESEVQVTVQGDKAVVS
FT                   FEPSAAPTPKNRIFAFSFLPSTAPSFPSPTRNPEVRTPKSATQPQTTETNLQTAPKL
FT                   (in isoform 10)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:7782315"
FT                   /id="VSP_037565"
FT   VAR_SEQ         213..241
FT                   /note="QPGFTGARCTENVPMKVQNQEKAEELYQK -> PNEFTGDRCQNYVMASFYS
FT                   TSTPFLSLPE (in isoform 8, isoform 9 and isoform 10)"
FT                   /evidence="ECO:0000303|PubMed:1350381,
FT                   ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:7509448, ECO:0000303|PubMed:7782315,
FT                   ECO:0000303|PubMed:8096067"
FT                   /id="VSP_003429"
FT   VAR_SEQ         213..234
FT                   /note="QPGFTGARCTENVPMKVQNQEK -> PNEFTGDRCQNYVMASFYKHLGIEFM
FT                   E (in isoform 6 and isoform 11)"
FT                   /evidence="ECO:0000303|PubMed:1350381,
FT                   ECO:0000303|PubMed:17565985, ECO:0000303|PubMed:7509448"
FT                   /id="VSP_003428"
FT   VAR_SEQ         213..233
FT                   /note="QPGFTGARCTENVPMKVQNQE -> PNEFTGDRCQNYVMASFY (in
FT                   isoform 7 and isoform 12)"
FT                   /evidence="ECO:0000303|PubMed:1350381,
FT                   ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:7509448"
FT                   /id="VSP_003427"
FT   VAR_SEQ         234..247
FT                   /note="KAEELYQKRVLTIT -> SAQMSLLVIAAKTT (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:7509448"
FT                   /id="VSP_003432"
FT   VAR_SEQ         234
FT                   /note="K -> KHLGIEFIE (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:7509448"
FT                   /id="VSP_003431"
FT   VAR_SEQ         242..640
FT                   /note="Missing (in isoform 8, isoform 9 and isoform 10)"
FT                   /evidence="ECO:0000303|PubMed:1350381,
FT                   ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:7509448, ECO:0000303|PubMed:7782315,
FT                   ECO:0000303|PubMed:8096067"
FT                   /id="VSP_003430"
FT   VAR_SEQ         248..640
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:7509448"
FT                   /id="VSP_003433"
FT   VAR_SEQ         424..640
FT                   /note="Missing (in isoform 12)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_046417"
FT   VAR_SEQ         424..462
FT                   /note="YVSAMTTPARMSPVDFHTPSSPKSPPSEMSPPVSSMTVS -> HNLIAELRR
FT                   NKAHRSKCMQIQLSATHLRSSSIPHLGFIL (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:7509448"
FT                   /id="VSP_003434"
FT   VAR_SEQ         463..640
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:7509448"
FT                   /id="VSP_003435"
FT   VARIANT         38
FT                   /note="R -> Q (in dbSNP:rs3924999)"
FT                   /evidence="ECO:0000269|PubMed:17565985"
FT                   /id="VAR_009307"
FT   VARIANT         289
FT                   /note="M -> T (in dbSNP:rs10503929)"
FT                   /evidence="ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:17565985"
FT                   /id="VAR_053531"
FT   VARIANT         463
FT                   /note="M -> K"
FT                   /id="VAR_009308"
FT   MUTAGEN         181
FT                   /note="K->E: Defective in integrin-binding and in inducing
FT                   ERBB3 phosphorylation; when associated with or without
FT                   E-185 or E-187. No effect on ERBB3-binding, defective in
FT                   integrin-binding and in ternary complex formation with
FT                   ERBB3 and integrins, and defective in inducing NRG1-ERBB
FT                   signaling; when associated with E-185 and E-187."
FT                   /evidence="ECO:0000269|PubMed:20682778"
FT   MUTAGEN         185
FT                   /note="K->E: Defective in integrin-binding and in inducing
FT                   ERBB3 phosphorylation; when associated with or without
FT                   E-181 or E-187. No effect on ERBB3-binding, defective in
FT                   integrin-binding and in ternary complex formation with
FT                   ERBB3 and integrins, and defective in inducing NRG1-ERBB
FT                   signaling; when associated with E-181 and E-187."
FT                   /evidence="ECO:0000269|PubMed:20682778"
FT   MUTAGEN         187
FT                   /note="K->E: Defective in integrin-binding and in inducing
FT                   ERBB3 phosphorylation; when associated with or without
FT                   E-181 or E-185. No effect on ERBB3-binding, defective in
FT                   integrin-binding and in ternary complex formation with
FT                   ERBB3 and integrins, and defective in inducing NRG1-ERBB
FT                   signaling; when associated with E-181 and E-185."
FT                   /evidence="ECO:0000269|PubMed:20682778"
FT   CONFLICT        94
FT                   /note="K -> A (in Ref. 2; AAA19953)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        107
FT                   /note="S -> P (in Ref. 10; ABQ53539)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        261
FT                   /note="V -> L (in Ref. 10; ABQ53540)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        414
FT                   /note="S -> F (in Ref. 2; AAA19953)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        535
FT                   /note="Q -> R (in Ref. 2; AAA19951)"
FT                   /evidence="ECO:0000305"
FT   STRAND          45..48
FT                   /evidence="ECO:0007829|PDB:7SJL"
FT   STRAND          51..61
FT                   /evidence="ECO:0007829|PDB:7SJL"
FT   STRAND          67..72
FT                   /evidence="ECO:0007829|PDB:7SJL"
FT   TURN            79..81
FT                   /evidence="ECO:0007829|PDB:7SJL"
FT   STRAND          86..91
FT                   /evidence="ECO:0007829|PDB:7SJL"
FT   STRAND          94..102
FT                   /evidence="ECO:0007829|PDB:7SJL"
FT   HELIX           104..106
FT                   /evidence="ECO:0007829|PDB:7SJL"
FT   STRAND          108..115
FT                   /evidence="ECO:0007829|PDB:7SJL"
FT   STRAND          120..130
FT                   /evidence="ECO:0007829|PDB:7SJL"
FT   STRAND          179..181
FT                   /evidence="ECO:0007829|PDB:3U7U"
FT   TURN            185..189
FT                   /evidence="ECO:0007829|PDB:3U7U"
FT   STRAND          190..193
FT                   /evidence="ECO:0007829|PDB:1HRE"
FT   STRAND          195..199
FT                   /evidence="ECO:0007829|PDB:3U7U"
FT   STRAND          200..204
FT                   /evidence="ECO:0007829|PDB:1HRE"
FT   STRAND          208..212
FT                   /evidence="ECO:0007829|PDB:3U7U"
FT   STRAND          216..218
FT                   /evidence="ECO:0007829|PDB:3U7U"
FT   STRAND          233..235
FT                   /evidence="ECO:0007829|PDB:1HAF"
FT   VARIANT         Q02297-10:46
FT                   /note="G -> R (in dbSNP:rs3735774)"
FT                   /evidence="ECO:0000305"
FT                   /id="VAR_082866"
FT   VARIANT         Q02297-10:127
FT                   /note="A -> P (in dbSNP:rs34822181)"
FT                   /evidence="ECO:0000305"
FT                   /id="VAR_082867"
SQ   SEQUENCE   640 AA;  70392 MW;  C30D3F614AADFF62 CRC64;
     MSERKEGRGK GKGKKKERGS GKKPESAAGS QSPALPPRLK EMKSQESAAG SKLVLRCETS
     SEYSSLRFKW FKNGNELNRK NKPQNIKIQK KPGKSELRIN KASLADSGEY MCKVISKLGN
     DSASANITIV ESNEIITGMP ASTEGAYVSS ESPIRISVST EGANTSSSTS TSTTGTSHLV
     KCAEKEKTFC VNGGECFMVK DLSNPSRYLC KCQPGFTGAR CTENVPMKVQ NQEKAEELYQ
     KRVLTITGIC IALLVVGIMC VVAYCKTKKQ RKKLHDRLRQ SLRSERNNMM NIANGPHHPN
     PPPENVQLVN QYVSKNVISS EHIVEREAET SFSTSHYTST AHHSTTVTQT PSHSWSNGHT
     ESILSESHSV IVMSSVENSR HSSPTGGPRG RLNGTGGPRE CNSFLRHARE TPDSYRDSPH
     SERYVSAMTT PARMSPVDFH TPSSPKSPPS EMSPPVSSMT VSMPSMAVSP FMEEERPLLL
     VTPPRLREKK FDHHPQQFSS FHHNPAHDSN SLPASPLRIV EDEEYETTQE YEPAQEPVKK
     LANSRRAKRT KPNGHIANRL EVDSNTSSQS SNSESETEDE RVGEDTPFLG IQNPLAASLE
     ATPAFRLADS RTNPAGRFST QEEIQARLSS VIANQDPIAV
//
